Nicotinamide Riboside

Nicotinamide riboside (NR) is a naturally occurring form of vitamin B3 found in small amounts in milk and certain other foods. It functions as a precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme central to cellular energy metabolism, DNA repair, and the regulation of proteins involved in stress responses and ageing. Interest in NR as a supplement is driven by evidence that NAD+ levels decline with age and in certain disease states, and by the hypothesis that restoring NAD+ through precursor supplementation might counteract aspects of biological ageing. NR entered clinical investigation in 2016 and has been studied in approximately 25 human trials since, making it one of the more extensively studied longevity-oriented compounds in this category — though not the most studied relative to the strength of claims made in the marketplace.

What it is

NR belongs to the vitamin B3 family alongside niacin, nicotinamide, and nicotinamide mononucleotide (NMN). It enters cells via equilibrative nucleoside transporters and is converted intracellularly to NMN by nicotinamide riboside kinases, then to NAD+. This pathway gives NR a distinct route to NAD+ synthesis compared with niacin and nicotinamide, and one that avoids the flushing associated with high-dose niacin. Whether NMN is converted to NR before cellular uptake, or whether direct NMN transporters exist in humans, remains an active area of scientific dispute, making direct comparison of NR and NMN difficult to interpret.

The commercial NR supplement market is dominated by a proprietary form called Niagen, manufactured by ChromaDex. Much of the early clinical evidence was conducted by investigators with financial relationships to ChromaDex, though independent academic trials have since been published. NR is also found in combination products alongside pterostilbene, a stilbene antioxidant, on the basis of proposed synergy with NAD+ metabolism; this combination has been tested in some trials but the evidence does not yet support conclusions about additive benefit.

NAD+ has multiple proposed mechanisms of relevance to ageing: it is a cofactor for sirtuins (deacetylase enzymes involved in DNA repair and metabolic regulation), for PARP enzymes (involved in DNA damage responses), and for CD38 (an enzyme whose activity increases with ageing and inflammation and consumes NAD+). The hypothesis that raising NAD+ via supplementation meaningfully activates these pathways in humans at concentrations achieved by oral dosing is plausible but not confirmed by clinical outcome data. Despite this detailed mechanistic rationale, clinical trials have not validated these pathways at the level of functional outcomes in humans.

What the evidence shows

The most important single synthesis of the NR human trial literature is the 2023 review by Damgaard and Treebak in Science Advances, which critically assessed all 25 published human NR supplementation studies available at the time. Its conclusions are direct: oral NR supplementation has shown few clinically relevant effects, and there is a tendency in the literature to overstate findings by emphasising statistically significant biomarker changes while underreporting null results on clinical outcomes. This characterisation should anchor how the broader evidence base is interpreted.

Across multiple populations and outcome domains, NR supplementation has repeatedly failed to demonstrate clinically meaningful benefit on primary endpoints. What NR does consistently and reliably is raise blood NAD+ levels. Across multiple trials, oral NR at doses of 300 to 1,000 mg per day produces two-fold or greater increases in whole-blood NAD+ and associated metabolites, including NAAD — the validated pharmacodynamic marker of NR-driven NAD+ synthesis. This effect is reproducible, dose-dependent, and not disputed. The question is what, if anything, this NAD+ elevation translates to in terms of human physiology.

On clinical functional outcomes, the picture is considerably less favourable. A 2025 systematic review and meta-analysis examining the effects of NR and NMN on skeletal muscle mass and function in older adults (Journal of Cachexia, Sarcopenia and Muscle) identified no clinically meaningful pooled benefit on muscle strength, muscle mass, or physical performance measures. Individual trials in middle-aged and older adults have found null results on primary endpoints including insulin sensitivity, aerobic capacity, blood pressure, body composition, and cardiovascular biomarkers. A five-month randomised twin study (Lapatto et al., 2023, Science Advances, n=40 twin pairs) found that NR improved muscle mitochondrial biogenesis markers and gut microbiota composition — providing the most mechanistically informative human evidence published to date — but did not improve adiposity, insulin sensitivity, or other metabolic health outcomes. A key concern flagged by Damgaard and Treebak is that some trials have reported unfavourable metabolic signals, including increased insulin resistance and body weight in one RCT, which were not highlighted prominently in the original publications. This finding has not been consistently replicated but remains unresolved.

Specific exploratory domains where signals exist but evidence is insufficient include cognitive function in mild cognitive impairment (one 10-week pilot study in 20 participants), cerebral blood flow changes on MRI, and symptom recovery in long-COVID (one 24-week trial in 58 participants, with high dropout and no significant between-group differences on primary cognitive endpoints). These represent hypothesis-generating findings rather than evidence of efficacy.

Five questions

Does low status cause harm? NAD+ declines with age, and severely depleted NAD+ is associated with cellular dysfunction in disease states and extreme ageing. However, the relevance of typical age-related NAD+ decline to supplementation in otherwise healthy adults has not been established. There is no defined clinical deficiency state for NR as distinct from general vitamin B3 adequacy, which is met by dietary intake. Whether the degree of NAD+ decline seen in normal ageing is causally responsible for functional decline — as opposed to being a correlate of other ageing processes — is not resolved.

Does supplementation prevent disease? There is no human evidence that NR supplementation prevents any disease. Trials in clinical populations — heart failure, peripheral artery disease, Parkinson's disease, mild cognitive impairment, long-COVID — have not demonstrated meaningful clinical benefit on primary endpoints. Disease prevention in healthy populations has not been tested in adequately powered long-term trials.

Does it affect biomarkers? Yes, reliably and consistently for NAD+ and related metabolites. Blood NAD+ elevation is the most robustly replicated effect of NR supplementation in humans. Changes in downstream biomarkers — including acylcarnitines, markers of mitochondrial function in muscle biopsy samples, and gut microbiota composition — have been observed in individual studies but are not consistent across trials. Whether NAD+ elevation in blood reflects meaningful changes in target tissue NAD+ levels — particularly in brain, liver, or skeletal muscle — remains unproven in most human trials. Blood NAD+ is not a validated surrogate for any clinical outcome. There is currently no evidence that raising blood NAD+ in this way produces downstream clinical benefit.

Does it help clinical populations? Clinical trials in populations with heart failure, peripheral artery disease, mild cognitive impairment, Parkinson's disease, and long-COVID have been conducted, but none has demonstrated significant improvement on its pre-specified primary endpoint. Most of these trials are small pilot studies designed to assess safety and feasibility rather than efficacy. The evidence does not currently support a claim that NR helps any clinical population.

Does it benefit healthy individuals? The evidence in healthy middle-aged and older adults — the population most likely to be purchasing NR supplements — has also failed to show consistent functional benefit. Trials in this population have examined muscle performance, metabolic health, cardiovascular function, and exercise capacity, with generally null results on primary endpoints. The twin study by Lapatto et al. provides some evidence that longer-duration supplementation produces measurable molecular changes in muscle and gut microbiota, but these did not translate to metabolic or functional outcomes over five months.

Individual variation

Baseline NAD+ levels vary considerably across individuals and are influenced by age, metabolic status, physical activity, alcohol consumption, and possibly genetics. There is a theoretical basis for expecting greater NAD+ elevation in response to NR supplementation in those with lower baseline NAD+, and some post-hoc analyses have suggested that individuals who achieve greater NAD+ increases may show modestly better functional responses. However, these observations are exploratory and have not been prospectively validated, and there is currently no clinical test that usefully stratifies who should or should not take NR.

Age is likely relevant to the magnitude of NAD+ elevation achievable, since baseline NAD+ is lower in older adults and the capacity of compensatory biosynthesis pathways declines with age. However, demonstrating that older adults achieve greater NAD+ increases does not resolve whether those increases are clinically meaningful.

Sex-specific data from NR trials are limited. Most trials have not reported sex-stratified outcomes. There is theoretical interest in NR in the context of perimenopause and menopause, where mitochondrial function in cardiac and skeletal muscle changes in response to oestrogen decline, but this has not been specifically investigated in adequately powered NR trials.

The NR versus NMN comparison is one of the most commonly searched supplement questions and is worth addressing directly. Both are NAD+ precursors with closely related metabolic fates. Human pharmacokinetic evidence suggests NR may achieve somewhat greater blood NAD+ elevation than NMN at equivalent doses, but head-to-head clinical outcome comparisons do not exist. Neither has demonstrated consistent clinical benefit, making the comparison less clinically meaningful than the marketing around it suggests.

Testing and status assessment

Blood NAD+ can be measured in research settings and is increasingly offered by commercial laboratories, but the clinical utility of such testing is not established. There are no agreed reference ranges for blood NAD+ that define a state requiring intervention, and the relationship between blood NAD+ and tissue NAD+ — which is what would matter for most proposed mechanisms — is not fully characterised. NAD+ testing should not be used to justify supplementation in clinical practice on current evidence.

Safety

Short-term trials suggest NR is generally well tolerated at doses up to 2,000 mg per day, but long-term safety is not established. Common mild adverse events include nausea, fatigue, flushing (at higher doses), and headache. No serious adverse events have been attributed to NR in published trials. Standard safety blood tests — including liver function, kidney markers, and haematological parameters — have not shown significant abnormalities in NR-treated groups.

Two safety signals warrant explicit attention. First, one randomised controlled trial in obese men found that NR supplementation was associated with increased insulin resistance compared to placebo. This finding was not the focus of the original publication and has not been consistently replicated, but it introduces sufficient uncertainty about metabolic effects to warrant caution, particularly in people with impaired glucose metabolism. Second, NR supplementation increases urinary excretion of methylnicotinamide, a nicotinamide catabolite, at higher doses. The significance of sustained elevation in methylnicotinamide is not well characterised, but preclinical evidence of adverse effects at high nicotinamide doses — including oxidative DNA damage and worsened lipid profiles in rodent models — provides a theoretical basis for monitoring.

Long-term safety beyond 12 weeks has not been established in randomised controlled trials. Most trials are short-term, and durability of any effect beyond 3 to 6 months is not established. Almost all published human data are from studies of 12 weeks or shorter duration. Safety in pregnancy and breastfeeding has not been studied. Safety in populations with significant organ disease is not well characterised beyond the limited trials in heart failure.

Drug interactions have not been systematically studied. NR is metabolised through vitamin B3 pathways, and the clinical relevance of interactions with medications affecting these pathways is not established.

What can reasonably be concluded

NR reliably raises blood NAD+ levels in humans. This is the most robustly supported claim that can be made. Whether raising blood NAD+ produces clinically meaningful benefit is the critical unresolved question, and the current evidence does not support an affirmative answer. An independent systematic review of 25 human trials concluded that NR has shown few clinically relevant effects, a conclusion that the overall pattern of null results on clinical primary endpoints across multiple populations supports. Mechanistic evidence from molecular studies — particularly the twin study showing effects on muscle mitochondrial biogenesis — is more encouraging but has not been accompanied by functional outcomes, and translation from molecular markers to clinical benefit in humans cannot be assumed.

The Emerging rating reflects a genuine and active but as yet clinically unvalidated research programme with a plausible biological mechanism, but a clinical evidence base that has not yet demonstrated meaningful human benefit in any population. The gap between the mechanistic story and the clinical outcome data is the defining feature of the NR literature. This gap may narrow as longer-duration trials in larger and more carefully selected populations are completed, but it has not narrowed yet.

Where evidence is limited or outcomes are uncertain, conclusions should be treated as provisional and subject to revision as the evidence base develops.